FALBERG KATHRYN E 4

What Happened

• Kathryn E. Falberg, a director of Arcus Biosciences (RCUS), was granted equity awards on June 11, 2026: 5,700 restricted stock units (RSUs) and derivative awards representing 16,900 shares. Both grants are reported at $0.00 acquisition price (award/ grant code A) — no cash changed hands. These awards increase her total economic interest to 52,600 shares (30,000 previously held directly + 22,600 newly granted).

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely — within the required reporting window).
• Award amounts: 5,700 RSUs and 16,900 derivative/share-based awards; reported acquisition price $0.00.
• Shares owned after transaction: 52,600 total (30,000 direct; 5,700 RSUs; 16,900 derivative).
• Footnotes:
  • RSUs (5,700) vest in full on the earlier of June 11, 2027 or the next annual meeting; they also vest on a change in control.
  • The 16,900 derivative awards are subject to the same vesting schedule; they will become fully vested and exercisable on a change in control.
  • The 30,000 figure noted is prior direct ownership included in the post-transaction total.
• Transaction code: A = Award/Grant. No sale, purchase, or exercise occurred.

Context

• Director equity awards are commonly part of standard compensation and do not by themselves indicate buying or selling sentiment. These grants are subject to time- and change-in-control vesting conditions; they are not immediately liquid shares unless and until vested (or exercised, if applicable).